Best COA Fields to Check Before Research Use

A peptide vial may carry the correct product name and stated quantity, yet those details alone do not establish what is inside it. The best COA fields to check are the ones that connect the physical material in hand to a defined batch, a stated specification and a credible analytical result. For researchers, that connection is the basis of traceability.

A Certificate of Analysis, or COA, should be read as a batch-specific quality document rather than a general marketing statement. It records what was tested, how the material performed against specification and which lot the results apply to. The value lies in the relationship between those fields. A purity figure without a batch number, for example, provides far less assurance than a complete document that can be matched to the product label.

Start with batch identity and product description

The first check is straightforward but non-negotiable: confirm that the product name on the COA corresponds to the material ordered and that the batch or lot number matches the vial, packaging or associated batch reference. The date of analysis and, where supplied, the manufacturing or retest date should also be logical for that batch.

Peptide names can look similar, particularly where sequence-related materials, salts or modified forms are involved. A COA should identify the material with sufficient precision to distinguish the intended research compound from a related product. For a peptide, this may include the full name, sequence, molecular formula, molecular weight or salt form.

A document that refers only to a broad product category is less useful than one tied to a specific, identifiable material. Likewise, a generic COA used across multiple batches cannot demonstrate the result for the vial currently being assessed. Batch-level documentation is what allows a researcher to maintain a meaningful record from receipt through to laboratory use.

What to compare against the label

Check the spelling of the product name, stated quantity, lot or batch number and any product code. If the COA identifies a molecular weight or formula, compare it with the expected form of the compound being sourced. Small discrepancies may sometimes reflect presentation conventions, but they should be resolved before the material enters a study workflow.

Best COA fields to check for identity

Identity testing addresses a basic question: does the analysed material correspond to the stated compound? For peptides, mass spectrometry is commonly used to support identity confirmation because it can assess whether the observed molecular mass aligns with the theoretical mass.

The COA should state the identity test method and report a result that is interpretable. Useful entries include an expected mass, an observed mass and a clear pass or conforms statement. A result is stronger when the document gives enough information to show what was compared, rather than simply stating “identity confirmed” without context.

Mass alone does not describe every aspect of a material’s composition. It does, however, form an important part of a wider quality review. The expected molecular weight should be appropriate for the specified peptide form. For example, differences in counter-ion, hydration state or modification can affect how a mass is represented. This is why identity must be considered alongside the product description and specification, not as an isolated number.

Where sequence information is included, it should correspond to the intended compound. For technically informed buyers, this is a useful additional control when distinguishing materials with similar names or related structures.

Read the purity result in context

Purity is often the first figure people look for, but it is not the only figure that matters. The COA should identify the analytical method used to measure it, commonly HPLC or a related chromatographic method, and state the acceptance criterion alongside the batch result.

A reported result such as “99% purity” is more meaningful when the document specifies whether this is HPLC area percentage, the chromatographic conditions or an applicable test method. Chromatographic purity describes the relative area of detectable peaks under a defined method. It is an essential quality indicator, but it is not automatically a complete account of peptide content, water content, residual solvents or all possible impurities.

Researchers should therefore avoid treating a single purity percentage as a universal measure of suitability. The appropriate specification depends on the study design, analytical sensitivity, control strategy and the role of the material in the work. A high purity result is valuable, but repeatable research also depends on correct identity, documented handling and a traceable batch record.

Look for a pass/fail relationship

A well-presented COA makes it easy to see the specification and the observed result together. For example, it may show an acceptance limit, a test result and a conclusion such as “conforms”. This format helps distinguish a measured batch result from a nominal claim.

Be cautious where the purity result is presented without a method, an acceptance criterion or a clear batch reference. It may still prompt a useful question, but it offers limited support for a formal laboratory record.

Review assay, content and moisture where relevant

Purity and assay are not interchangeable terms. Purity generally reflects separation of the primary component from chromatographically detectable related substances. Assay or peptide content may address how much active peptide is present by mass, depending on the method and specification. A researcher preparing quantitative work should understand which measurement is being supplied.

For lyophilised peptides, water content can also affect calculations and handling expectations. Methods such as Karl Fischer titration may be used where moisture is included within the specification. Residual solvent testing can be relevant as well, particularly where the material’s manufacturing and drying process calls for that control.

Not every COA will display every possible test. The right document reflects the material, the supplier’s quality system and the intended specification. What matters is that omitted fields are not quietly assumed to have been tested. If a parameter is critical to a particular protocol, it should be verified through the available documentation before work begins.

Check the method, specification and laboratory details

Analytical results need a framework. A credible COA identifies the methods used, whether through named techniques, method references or both. It should also make clear what the material was required to meet. “Conforms” is useful only when the underlying requirement is defined.

The document should carry an issue date and appropriate quality authorisation, such as a signature, approval statement or responsible department. Supplier and laboratory details should be coherent and sufficiently clear to support follow-up if a record needs clarification. Depending on the supply arrangement, the testing laboratory may be the manufacturer, an internal quality function or an independent analytical laboratory. Independence can be valuable, but the essential point is that the report is attributable, batch-specific and technically legible.

A COA is not strengthened merely by having a logo or formal layout. Look for consistency between the heading, sample identification, methods, results and release decision. Mismatched product names, unexplained dates or absent specifications are practical reasons to pause and investigate.

Use traceability as part of your receiving process

The COA should not sit separately from the material it describes. On receipt, record the batch number, date received, stated quantity, storage condition and COA version in the laboratory’s inventory or sample log. Retain the original document with the record, whether digitally or in controlled hard copy.

This approach becomes particularly valuable when a project runs over several weeks or uses multiple batches. If results differ unexpectedly, traceability allows the team to review whether a change in batch, storage exposure, reconstitution approach or handling condition may be relevant. It does not establish causation by itself, but it prevents avoidable gaps in the investigation.

At 23 Bio Labs, batch references and COA documentation are intended to support this practical chain of custody. Researchers should still verify that the reference supplied corresponds to the material received and follow the stated storage guidance from the point of delivery.

Consider storage and retest information carefully

A COA may include recommended storage conditions, retest dates or expiry information. These fields help define how the material was evaluated and how it should be protected, but they do not replace controlled handling in the laboratory.

For lyophilised research peptides, storage conditions may differ before and after reconstitution. Repeated warming, unnecessary exposure to moisture and inconsistent temperature control can affect material integrity even where the original batch met specification at release. Record any reconstitution date, solvent used and storage condition alongside the batch number.

A retest date should also be read correctly. It typically indicates the period for which a material may be reassessed under stated storage conditions; it is not a guarantee that every vial has been handled correctly after dispatch. If packaging is compromised, labels are unreadable or storage conditions are unknown, documentation cannot fully remove that uncertainty.

A practical decision standard for COA review

Before accepting a peptide for research use, the document should allow you to answer a short set of operational questions: Is this the exact product and batch received? Was identity assessed by a stated method? Does the purity result meet a defined specification? Are relevant content or moisture considerations documented for the intended work? Can the result be traced to a dated and authorised quality record?

The required depth of review depends on the work. A preliminary non-clinical research exercise may require a different documentation threshold from a tightly controlled comparative study. Even so, the same principle applies: do not let an impressive purity percentage substitute for complete, batch-specific evidence.

Careful COA review is a small step at receipt, but it protects the quality of every decision that follows. When documentation, labelling and handling records agree, researchers can spend less time reconstructing material history and more time carrying out controlled, responsible work.